The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology
Open accessAbstract
Importance: To date, the benefit of genome-driven cancer therapy has not been quantified. Objective: We sought to estimate the annual percentage of patients in the United States with advanced or metastatic cancer who could be eligible for and benefit from US Food and Drug Administration (FDA)-approved genome-driven therapy from 2006 to 2018. Design, Setting, and Participants: Retrospective cross-sectional study using publically available data of (1) demographic characteristics of patients with advanced or metastatic cancer; (2) FDA data on cancer drugs approved from January 2006 through January 2018; (3) measures of response and duration of response from drug labels; and (4) published reports estimating the frequency of various genomic aberrations used to estimate what percentage of patients would have been eligible for and would have benefited from genome-driven therapy during the studied period. Main Outcomes and Measures: Estimated percentage of US patients with cancer eligible for and benefiting from genome-targeted and genome-informed therapy by year, response rate of genome-informed indications, and duration of response. Results: A total of 31 drugs with 38 FDA-approved indications met our inclusion criteria for genome-targeted or genome-informed therapy from January 1, 2006, through January 31, 2018. The estimated number of patients eligible for genome-targeted therapy in 2006 was 28 729 of a total 564 830 patients with metastatic cancer, or 5.09% (95% CI, 5.03%-5.14%). By 2018, this number had increased to 50 811 of 609 640, or 8.33% (95% CI, 8.26%-8.40%). For genome-informed therapy in 2006, the eligible number of patients was 59 301 of 564 830, or 10.50% (95% CI, 10.42%-10.58%). In 2018, genome-informed treatment could be offered to 94 157 of 609 640, or 15.44% (95% CI, 15.35%-15.53%) of patients with metastatic cancer. The percentage of patients with cancer estimated to benefit from genome-targeted therapy in 2006 was 0.70% (95% CI, 0.68%-0.72%), and in 2018, it had increased to 4.90% (95% CI, 4.85%-4.95%). For genome-informed treatment in 2006, the percentage estimated to benefit was 1.31% (95% CI, 1.28%-1.34%), and in 2018, it had increased to 6.62% (95% CI, 6.56%-6.68%). The median overall response rate for all genome-informed drugs through January 2018 was 54%, and the median duration of response was 29.5 months. Conclusions and Relevance: Although the number of patients eligible for genome-driven treatment has increased over time, these drugs have helped a minority of patients with advanced cancer. To accelerate progress in precision oncology, novel trial designs of genomic therapies should be developed, and broad portfolios of drug development, including immunotherapeutic and cytotoxic approaches, should be pursued.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rogers, E. M., Singhal, A., & Quinlan, M. M. (2019) · An Integrated Approach to Communication Theory and Research · doi:10.4324/9780203710753-35 · Cited by 37,322
Valente, T. W. (2003) · Genetics in Medicine · doi:10.1097/01.gim.0000061743.67794.c4 · Cited by 13,723
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Lung Cancer: Epidemiology, Etiology, and Prevention
Dela Cruz, C. S., Tanoue, L. T., & Matthay, R. A. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.09.001 · Cited by 2,484
Toward a Shared Vision for Cancer Genomic Data
Grossman, R. L., Heath, A. P., Ferretti, V., Varmus, H. E., Lowy, D. R., Kibbe, W. A., & Staudt, L. M. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1607591 · Cited by 1,680
Massard, C., Michiels, S., Ferté, C., Le Deley, M.-C., Lacroix, L., Hollebecque, A., Verlingue, L., Ileana, E., Rosellini, S., Ammari, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1396 · Cited by 783
Implementing Genome-Driven Oncology
Hyman, D. M., Taylor, B. S., & Baselga, J. (2017) · Cell · doi:10.1016/j.cell.2016.12.015 · Cited by 503
Limits to Personalized Cancer Medicine
Tannock, I. F., & Hickman, J. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmsb1607705 · Cited by 415
Functional precision cancer medicine—moving beyond pure genomics
Letai, A. (2017) · Nature Medicine · doi:10.1038/nm.4389 · Cited by 366
Genomics-Driven Oncology: Framework for an Emerging Paradigm
Garraway, L. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.8934 · Cited by 340
Perspective: The precision-oncology illusion
Prasad, V. (2016) · Nature · doi:10.1038/537s63a · Cited by 292
Self-citationPrecision oncology: origins, optimism, and potential
Prasad, V., Fojo, T., & Brada, M. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00620-8 · Cited by 254
Self-citationCancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study
Wheler, J. J., Janku, F., Naing, A., Li, Y., Stephen, B., Zinner, R., Subbiah, V., Fu, S., Karp, D., Falchook, G. S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3043 · Cited by 238
Future cancer research priorities in the USA: a Lancet Oncology Commission
Jaffee, E. M., Dang, C. V., Agus, D. B., Alexander, B. M., Anderson, K. C., Ashworth, A., Barker, A. D., Bastani, R., Bhatia, S., Bluestone, J. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30698-8 · Cited by 208
Zia, M. I., Siu, L. L., Pond, G. R., & Chen, E. X. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.679 · Cited by 157
Self-citationMolecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014
Morgensztern, D., Campo, M. J., Dahlberg, S. E., Doebele, R. C., Garon, E. B., Gerber, D. E., Goldberg, S. B., Hammerman, P. S., Heist, R. S., Hensing, T. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000405 · Cited by 149
Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time
Chia, S., Low, J.-L., Zhang, X., Kwang, X.-L., Chong, F.-T., Sharma, A., Bertrand, D., Toh, S. Y., Leong, H. S., Thangavelu, M. T., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00451-5 · Cited by 94
Enewold, L., & Thomas, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156728 · Cited by 82
Genomic Alteration–Driven Clinical Trial Designs in Oncology
Simon, R. M. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2413 · Cited by 46
No Solid Evidence, Only Hollow Argument for Universal Tumor Sequencing: Show Me the Data
West, H. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0075 · Cited by 43
Wagner, J., Marquart, J. P., Ruby, J., Lammers, A. J., Mailankody, S., Kaestner, V., & Prasad, V. K. (2018) · BMJ · doi:10.1136/bmj.k668 · Cited by 43
Self-citationSkaga, E., Kulesskiy, E., Brynjulvsen, M., Sandberg, C. J., Potdar, S., Langmoen, I. A., Laakso, A., Gaál‐Paavola, E., Perola, M., Wennerberg, K., et al. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0253-6 · Cited by 31
Precision oncology: a strategy we were not ready to deploy
Fojo, T. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.01.005 · Cited by 24
Prasad, V. K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx786 · Cited by 19
Self-citationParikh, D. A., Walia, G., Freeman‐Daily, J., Hennink, M., Tomalia, T., Buonnano, L., Goldman, L., Addario, B. J., & Patel, M. I. (2019) · JCO Oncology Practice · doi:10.1200/jop.19.00135 · Cited by 15
Can We Define and Reach Precise Goals for Precision Medicine in Cancer Care?
West, H. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.8226 · Cited by 14
Patients with FLT3-mutant AML needed to enroll on FLT3-targeted therapeutic clinical trials
Bucy, T., Zoscak, J. M., Mori, M., & Borate, U. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000532 · Cited by 3
Cited by
Palma, D. A., Olson, R., Harrow, S., Gaede, S., Louie, A. V., Haasbeek, C., Mulroy, L., Lock, M., Rodrigues, G. B., Yaremko, B. P., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32487-5 · Cited by 1,857
Haslam, A., & Prasad, V. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.2535 · Cited by 1,413
Self-citationGLOBOCAN 2020 Report on Global Cancer Burden: Challenges and Opportunities for Surgical Oncologists
Deo, S. V. S., Sharma, J., & Kumar, S. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12151-6 · Cited by 489
Diffuse Glioma Heterogeneity and Its Therapeutic Implications
Nicholson, J. G., & Fine, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1474 · Cited by 460
MOLI: multi-omics late integration with deep neural networks for drug response prediction
Sharifi-Noghabi, H., Zolotareva, O., Collins, C. C., & Ester, M. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz318 · Cited by 421
Metadata
- Authors
- Marquart, J., Chen, E. Y., & Prasad, V.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2018-08-01
- Volume
- 4
- Issue
- 8
- Pages
- 1093
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2802321540
- Cited by
- 377
- References
- 29
- FWCI
- 12.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.